NEW YORK, Sept. 14 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB - News) - GENova Biotherapeutics Inc. (“GENova”) today announced that it is preparing for patent application filings in both the US (at the FDA (U.S. Food and Drug Administration (www.fda.gov) for a 510(k) submission) and in Europe through EMEA (European Medicines Agency) subsequent to expected efficacious and non-toxic pre-clinical results for Prostaganin.
Prostaganin: Peptide for prostate cancer
For humans, one of the peptides’ most important qualities is the ability to demonstrate complete inhibition of growth of prostate tumour xenografts. Furthermore, they can markedly reduce the secretion of the prostate-specific antigen (PSA), a biomarker widely known to be indicative of this malignancy. Therefore, GENova’s Prostaganin is a candidate for development of an anti-cancer medicament for treatment of humans.
Representing the most commonly diagnosed non-cutaneous cancer in ageing males, prostate cancer is the second leading cause of death in North American men. At present, the anti-androgen and LHRH analog drug classes dominate the market. However, with the development of a number of innovative therapies entering the market for the first time, the prostate cancer market will enter a more dynamic and high growth phase. By now, the market for prostate cancer therapies amounts to US$1.5 billion (Drugresearcher.com). But as newer and more innovative therapies are applied, the market is set to experience double digit growth and GENova wants to participate in this rapidly growing market.
About GENova Biotherapeutics Inc.
GENova is positioning itself as the world’s leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.
Forward Looking Statements
This document includes certain statements that may be deemed to be “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.
